R. Mondéjar

695 total citations
23 papers, 380 citations indexed

About

R. Mondéjar is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, R. Mondéjar has authored 23 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in R. Mondéjar's work include Cancer Immunotherapy and Biomarkers (5 papers), Lymphoma Diagnosis and Treatment (4 papers) and CAR-T cell therapy research (3 papers). R. Mondéjar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Lymphoma Diagnosis and Treatment (4 papers) and CAR-T cell therapy research (3 papers). R. Mondéjar collaborates with scholars based in Spain, United States and Chile. R. Mondéjar's co-authors include Rámón Colomer, O. Donnay, Vilma Pacheco-Barcía, Jacobo Rogado, J.M. Sánchez-Torres, Ana M. Ramos‐Leví, Pedro Gullón, Javier Aspa, Arántzazu Alfranca and Magdalena Adrados and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

R. Mondéjar

23 papers receiving 375 citations

Peers

R. Mondéjar

ONCOL

NEURO

PRM

IMMUN

Ken Takeshima Japan

Jake Allred United States

J Shimizu Japan

Mojgan Devouassoux France

Hiroyuki Hiraki Japan

Carla Manzitti Italy

Rajesh Patidar India

Zhixia Yue China

C. Barile Italy

Matthias Beyens Belgium

Ken Takeshima Japan

R. Mondéjar

168 ×0.8

ONCOL

66 ×0.9

NEURO

47 ×0.7

PRM

67 ×1.3

IMMUN

56 ×1.2

Citations per year, relative to R. Mondéjar R. Mondéjar (= 1×) peers Ken Takeshima

Countries citing papers authored by R. Mondéjar

Since Specialization

Citations

This map shows the geographic impact of R. Mondéjar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Mondéjar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Mondéjar more than expected).

Fields of papers citing papers by R. Mondéjar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Mondéjar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Mondéjar. The network helps show where R. Mondéjar may publish in the future.

Co-authorship network of co-authors of R. Mondéjar

This figure shows the co-authorship network connecting the top 25 collaborators of R. Mondéjar. A scholar is included among the top collaborators of R. Mondéjar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Mondéjar. R. Mondéjar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mondéjar, R., et al.. (2022). Clinical Evaluation of Serum Levels of SARS-CoV-2 Anti-Spike Protein IgG Antibodies in Infected Patients and Vaccinated Subjects. Clinical Laboratory. 68(07/2022). 3 indexed citations

Mondéjar, R., et al.. (2021). Utility of icteric index in clinical laboratories: more than a preanalytical indicator. Biochemia Medica. 31(2). 258–266. 6 indexed citations

García‐Alfonso, Pilar, Miriam Saiz‐Rodríguez, R. Mondéjar, et al.. (2021). Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical & Translational Oncology. 24(3). 483–494. 31 indexed citations

France, T., Jamil Asselah, R. Mondéjar, et al.. (2020). 153P The Systemic Inflammation Response Index (SIRI) is a prognostic factor that correlates with tumor burden in advanced pancreatic cancer. Annals of Oncology. 31. S300–S300. 1 indexed citations

Mondéjar, R., Nerea Martı́nez, Cristina Pérez, et al.. (2020). Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. Scientific Reports. 10(1). 6721–6721. 10 indexed citations

Rogado, Jacobo, J.M. Sánchez-Torres, Nuria Romero-Laorden, et al.. (2019). Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients. European Journal of Cancer. 109. 21–27. 192 indexed citations

Rogado, Jacobo, R. Mondéjar, Nuria Romero-Laorden, et al.. (2018). 190P Are neutrophil-to-lymphocyte ratio (NLR) and neutrophil count percentage (NCP) predictors of nivolumab outcome and toxicity in NSCLC?. Journal of Thoracic Oncology. 13(4). S114–S114. 1 indexed citations

Rogado, Jacobo, R. Mondéjar, O. Donnay, et al.. (2018). 187P Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response. Journal of Thoracic Oncology. 13(4). S112–S112. 2 indexed citations

Witzig, Thomas E., Lubomir Sokol, Eric D. Jacobsen, et al.. (2018). Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood. 132(Supplement 1). 2937–2937. 2 indexed citations

10.

Mondéjar, R., Cristina Fernández, Arantza Onaindía, et al.. (2017). Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines. PLoS ONE. 12(5). e0177524–e0177524. 3 indexed citations

11.

Witzig, Thomas E., Lubomir Sokol, Eric D. Jacobsen, et al.. (2017). PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. Hematological Oncology. 35(S2). 251–252. 4 indexed citations

12.

Mondéjar, R. & Miguel Lucas. (2017). Molecular diagnosis in cerebral cavernous malformations. SHILAP Revista de lepidopterología. 32(8). 540–545. 3 indexed citations

13.

Mondéjar, R. & Miguel Lucas. (2015). Diagnóstico molecular de cavernomatosis cerebral. Neurología. 32(8). 540–545. 5 indexed citations

14.

Mondéjar, R., Francisco Solano, Ángel Pérez Sempere, et al.. (2014). Mutation Prevalence of Cerebral Cavernous Malformation Genes in Spanish Patients. PLoS ONE. 9(1). e86286–e86286. 30 indexed citations

15.

Mondéjar, R., et al.. (2014). Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clinica Chimica Acta. 431. 174–178. 29 indexed citations

16.

Mondéjar, R., J M García-Moreno, Francisco Solano, et al.. (2014). Clinical and Molecular Study of the Extracellular Matrix Protein 1 Gene in a Spanish Family with Lipoid Proteinosis. Journal of Clinical Neurology. 10(1). 64–64. 9 indexed citations

17.

Mondéjar, R., et al.. (2013). Pseudo-hypertriglyceridaemia or hyperglycerolemia?. Clínica e Investigación en Arteriosclerosis. 25(3). 123–126. 6 indexed citations

18.

Guzmán, José M., M.J. Donáte Moreno, J.M. Giménez Bachs, et al.. (2005). Fístula entero-neovejiga ileal: a propósito de dos casos. Actas Urológicas Españolas. 29(8). 782–786. 4 indexed citations

19.

Mondéjar, R., et al.. (2002). MRI findings in a remitting-relapsing case of Bickerstaff encephalitis. Neuroradiology. 44(5). 411–414. 28 indexed citations

20.

Mondéjar, R., et al.. (1996). [Eosinophilic cystitis and glandular-cystic cystitis as pseudotumor lesions].. PubMed. 49(2). 179–83. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact